TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03913923

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-217
Description: Combination of anti-CTLA-4 and anti-PD-1 monoclonal antibodies, 1mg/kg and 3 mg/mg, respectively, given Q3W as IV infusion for first 4 blinded infusions
Study: NCT04587713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 [Tablet B]
Description: TD-1473 \[Tablet B\] (2 Tablets = Dose A) current clinical tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 [Tablet B]
Description: TD-1473 \[Tablet B\] (2 Tablets = Dose A) current clinical tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 [Tablet B]
Description: TD-1473 \[Tablet B\] (2 Tablets = Dose A) current clinical tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 [Tablet B]
Description: TD-1473 \[Tablet B\] (2 Tablets = Dose A) current clinical tablet formulation
Study: NCT03913923

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCD-100
Description: Anti-PD-1 monoclonal antibody, 3 mg/kg, given Q3W as IV infusion for first 4 blinded infusions, after - 1 mg/kg, given Q2W as IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-100
Description: Anti-PD-1 monoclonal antibody, 3 mg/kg, given Q3W as IV infusion for first 4 blinded infusions, after - 1 mg/kg, given Q2W as IV infusion
Study: NCT04587713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 [Tablet B]
Description: TD-1473 \[Tablet B\] (2 Tablets = Dose A) current clinical tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 [Tablet B]
Description: TD-1473 \[Tablet B\] (2 Tablets = Dose A) current clinical tablet formulation
Study: NCT03185078

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy
Description: Extracorporeal shock wave therapy (ESWT) is a treatment method for the application of single-pulse acoustic pressure waves generated by sudden changes in pressure by creating shock waves with piezoelectric, electrohydraulic and electromagnetic systems. It has been reported that ESWT treatment is effective in the treatment of pain with hyperstimulation analgesia by inhibiting afferent pain receptors, and also improve angiogenesis and restore and reorganize the musculoskeletal system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy
Description: Extracorporeal shock wave therapy (ESWT) is a treatment method for the application of single-pulse acoustic pressure waves generated by sudden changes in pressure by creating shock waves with piezoelectric, electrohydraulic and electromagnetic systems. It has been reported that ESWT treatment is effective in the treatment of pain with hyperstimulation analgesia by inhibiting afferent pain receptors, and also improve angiogenesis and restore and reorganize the musculoskeletal system
Study: NCT03913923

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT02794415

Intervention type: OTHER
Group type: OTHER
Intervention: Community-based exercise
Description: Intervention Phase (6 months): The HIV Community-Based Exercise (CBE) intervention is a 6-month exercise program at the Central Toronto YMCA. Participants will meet the fitness instructor to establish an individualized exercise program that will include a combination of aerobic, resistive, neuromotor and flexibility training. Participants will attend exercise sessions for \~1.5 hour, 3 times per week for 24 weeks. Sessions will be supervised weekly by a fitness instructor.~Post-Intervention Phase (8 months): At the end of the 24 week intervention, participants will be encouraged to continue to engage in unsupervised exercise 3 times per week. As per usual practice at the YMCA, a fitness instructor will be available to monitor participants monthly.
Study: NCT02741323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Initial dose of 300 mg twice daily (150mg twice daily if co-prescribed with a potent CYP3A inhibitor or 600mg twice daily if co-prescribed with a potent CYP3A inducer). Will be modified if GFR \< 30, if co-prescribed with a potent CYP3A inhibitor or inducer, or if the calcineurin inhibitor used for maintenance immunosuppression is changed to cyclosporine (which is only allowed for tacrolimus toxicity).~Once GFR is greater than or equal to 30, the dose should be returned to the non-renal dosage. If GFR is consistently fluctuating (especially immediately post-transplant), the site investigator may choose when to resume normal dosing of study product based on clinical assessment of stability.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Initial dose of 300 mg twice daily (150mg twice daily if co-prescribed with a potent CYP3A inhibitor or 600mg twice daily if co-prescribed with a potent CYP3A inducer). Will be modified if GFR \< 30, if co-prescribed with a potent CYP3A inhibitor or inducer, or if the calcineurin inhibitor used for maintenance immunosuppression is changed to cyclosporine (which is only allowed for tacrolimus toxicity).~Once GFR is greater than or equal to 30, the dose should be returned to the non-renal dosage. If GFR is consistently fluctuating (especially immediately post-transplant), the site investigator may choose when to resume normal dosing of study product based on clinical assessment of stability.
Study: NCT01806623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Single oral dose of 150mg Fluconazole
Study: NCT01240187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perampanel
Description: Single dose of 6 tablets 2 mg orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perampanel
Description: Single dose of 1 tablet 12 mg orally
Study: NCT02521987

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 8mm port
Description: Participate in this arm will have their procedure performed with an 8mm laparoscopic port.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 12mm port
Description: Participate in this arm will have their procedure performed with a 12mm laparoscopic port.
Study: NCT03185078

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo ESWT
Description: In the placebo application, rESWT device was switched on but without pressing the pedal during the same session period. The applicator was positioned to be the same as the other groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo ESWT
Description: In the placebo application, rESWT device was switched on but without pressing the pedal during the same session period. The applicator was positioned to be the same as the other groups.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo ESWT
Description: In the placebo application, rESWT device was switched on but without pressing the pedal during the same session period. The applicator was positioned to be the same as the other groups.
Study: NCT01355965

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous T cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous T cells
Study: NCT03057418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aurixim
Description: Administration will be performed once a week during 4-week induction period, and then once per 12 weeks during supporting period, if necessary. Total maximum duration of the investigational therapy - 1 year, during which patients will receive up to 8 infusions of Aurixim.
Study: NCT00390689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.125 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.125 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.5 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.5 mg tablet
Study: NCT01396564

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 850 mg of Metformin daily, increased to 1700 mg after 12 weeks, for the duration of the trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: 15 mg of pioglitazone daily, increased to 60 mg after 12 weeks.
Study: NCT00092001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib 50 mg by oral capsule daily for 4 weeks in every 6 week cycle until progression or unacceptable toxicity.
Study: NCT01808326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorambucil, tablets
Description: 2mg tablets, chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles
Study: NCT03045835

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BASKA mask
Description: Baska mask will be inserted during induction of anaesthesia and once patient is in an adequate anaesthetic depth
Study: NCT00350545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2;IV infusion once weekly for four doses (days 1,8,15,22); option for second 4-week course at week 9
Study: NCT03045835

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation
Description: Endotracheal intubation will be carried out during induction of anaesthesia and once patient is in an adequate anaesthetic depth
Study: NCT00350545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 1 mg/kg; po per day with taper

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: trough 200-300 or lower; po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: trough 5-10 or lower; po
Study: NCT01493622

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: minocycline
Description: variable dose SGA and minocycline,100mg per capsule po（take orally） bid，16 weeks；

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: variable dose SGA and 100mg per capsule po（take orally） bid，16 weeks；
Study: NCT03143023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arginine toothpaste
Description: acid neutralizer toothpaste

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluoride toothpaste
Description: bactericidal toothpaste
Study: NCT03966066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erythromycin
Description: 3-5mg/kg.d orally for 6 months
Study: NCT00464685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Initial intravitreal injection of 700 µg dexamethasone with up to 1 additional treatment based on re-treatment criteria.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Initial sham injection with up to 1 additional treatment based on re-treatment criteria.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Photocoagulation
Description: Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Laser Photocoagulation
Description: Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.
Study: NCT01587313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate / hydralazine capsules
Description: Group 1: Day 1:Two SR capsules; Day 8: One IR capsule Group 2: Day 1:Two SR capsules; Day 8: One IR capsule Group 3: Day 1:Two SR capsules; Day 8: One IR capsule Group 4: Day 1:One IR capsule and two SR capsules; Day 8: Commercial BiDil Tablet tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate / hydralazine capsules
Description: Group 1: Day 1:Two SR capsules; Day 8: One IR capsule Group 2: Day 1:Two SR capsules; Day 8: One IR capsule Group 3: Day 1:Two SR capsules; Day 8: One IR capsule Group 4: Day 1:One IR capsule and two SR capsules; Day 8: Commercial BiDil Tablet tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate / hydralazine capsules
Description: Group 1: Day 1:Two SR capsules; Day 8: One IR capsule Group 2: Day 1:Two SR capsules; Day 8: One IR capsule Group 3: Day 1:Two SR capsules; Day 8: One IR capsule Group 4: Day 1:One IR capsule and two SR capsules; Day 8: Commercial BiDil Tablet tid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide dinitrate / hydralazine capsules
Description: Group 1: Day 1:Two SR capsules; Day 8: One IR capsule Group 2: Day 1:Two SR capsules; Day 8: One IR capsule Group 3: Day 1:Two SR capsules; Day 8: One IR capsule Group 4: Day 1:One IR capsule and two SR capsules; Day 8: Commercial BiDil Tablet tid
Study: NCT00596635

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Once Daily Cranberry Capsule
Description: 650mg capsule pure cranberry powder

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Twice Daily Cranberry Capsules
Description: One 650mg cranberry capsule administered twice per day
Study: NCT03622450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colistin
Description: Polymyxins are bactericidal drugs that bind to lipopolysaccharides (LPS) and phospholipids in the outer cell membrane of gram-negative bacteria.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbapenem + Aminoglycoside/ Quinolone
Description: Dual antipseudomonal given as IV for ventilator associated pneumonia for patients with Multi-drug resistant bacteria risk factors
Study: NCT02270268

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pectin
Description: Pectin （Andeli Ltd. Yantai, China）, 24g/d for six weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin
Study: NCT02338180

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: proximal preventive sealants
Description: On sound mesial surfaces of first permanent molars adjacent to a caries active lesion of second primary molar, after 4-6 days with an orthodontic separating rubber ring around the approximal contact area. The test site was isolated with cotton rolls or a rubber dam. The surface of 6m was etched with 35% phosphoric acid for 20 sec, washed with water and then air-dried. The sealant (Concise Sealant; 3M ESPE) was applied and light-cured for 20 sec each on the occlusal, buccal and lingual sides. After polymerization, the sealant was inspected for complete coverage.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: proximal preventive sealants
Description: On sound mesial surfaces of first permanent molars adjacent to a caries active lesion of second primary molar, after 4-6 days with an orthodontic separating rubber ring around the approximal contact area. The test site was isolated with cotton rolls or a rubber dam. The surface of 6m was etched with 35% phosphoric acid for 20 sec, washed with water and then air-dried. The sealant (Concise Sealant; 3M ESPE) was applied and light-cured for 20 sec each on the occlusal, buccal and lingual sides. After polymerization, the sealant was inspected for complete coverage.
Study: NCT03088059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Afatinib 40 mg given orally, once daily, 1 cycle is 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Afatinib 40 mg given orally, once daily, 1 cycle is 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib 125 mg given orally, once daily, 1 cycle is 28 days (21 days on treatment, then 7 days off)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard of care
Description: Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard of care
Description: Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard of care
Description: Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard of care
Description: Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPH2201
Description: protocol v2.0 and 2.1 : Monalizumab 10mg/kg given intravenously over 60 minutes, once every 14 days, 1 cycle is 14 days protocol v4.0 : Monalizumab 750mg given intravenously over 60 minutes, once every 28 days, 1 cycle is 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPH2201
Description: protocol v2.0 and 2.1 : Monalizumab 10mg/kg given intravenously over 60 minutes, once every 14 days, 1 cycle is 14 days protocol v4.0 : Monalizumab 750mg given intravenously over 60 minutes, once every 28 days, 1 cycle is 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500mg given intravenously over 60 minutes, once every 28 days, 1 cycle is 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib 300 mg given orally, once daily, 1 cycle is 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib 300 mg given orally, once daily, 1 cycle is 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01876
Description: INCAGN01876 300 mg given intravenously over 30 minutes, once every 14 days, 1 cycle is 28 days
Study: NCT02338180

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: proximal therapeutic sealant
Description: On mesial surfaces of first permanent molars with caries active lesion adjacent to a caries active lesion of second primary molar , after 4-6 days with an orthodontic separating rubber ring around the approximal contact area. The test site was isolated with cotton rolls or a rubber dam. The surface of 6m was etched with 35% phosphoric acid for 20 sec, washed with water and then air-dried. The sealant (Concise Sealant; 3M ESPE) was applied and light-cured for 20 sec each on the occlusal, buccal and lingual sides. After polymerization, the sealant was inspected for complete coverage.
Study: NCT02223676

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical pharmacists conduct medication history
Description: pharmacists conduct medication history before the physician interviews the patient and does not spend time on conducting medical history
Study: NCT01969370

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Option to request non-medically actionable incidental information (after receiving education about them)
Study: NCT02225418

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: saline
Study: NCT04015362

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sub-threshold intermittent pulsed magnetic stimulation
Description: Application of sub-threshold intermittent pulsed magnetic stimulation to spinal cord

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Application of sham magnetic stimulation to spinal cord
Study: NCT02159638

Intervention type: DEVICE
Group type: OTHER
Intervention: Guardian Enlite sensor
Description: Sensor insertion

Intervention type: DEVICE
Group type: OTHER
Intervention: Dexcom G4 platinum sensor
Description: Sensor insertion
Study: NCT02997163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Daily oral doses of talazoparib 0.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Daily oral doses of talazoparib 0.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Daily oral doses of talazoparib 0.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Daily oral doses of talazoparib 0.5 mg
Study: NCT03604003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: potassium losartan
Description: treated with bedtime or awakening doses of potassium losartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: potassium losartan
Description: treated with bedtime or awakening doses of potassium losartan
Study: NCT02337764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVP-1012 1mg
Description: TVP-1012 1mg Tablets
Study: NCT04172233

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK101
Description: AK101 is an anti-IL-12/23p40 monoclonal antibody.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK101
Description: AK101 is an anti-IL-12/23p40 monoclonal antibody.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK101
Description: AK101 is an anti-IL-12/23p40 monoclonal antibody.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK101
Description: AK101 is an anti-IL-12/23p40 monoclonal antibody.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK101
Description: AK101 is an anti-IL-12/23p40 monoclonal antibody.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK101
Description: AK101 is an anti-IL-12/23p40 monoclonal antibody.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: AK101
Description: AK101 is an anti-IL-12/23p40 monoclonal antibody.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo